



FIRST-QUARTER 2022 RESULTS

TOTAL COMPANY

\$11.9B

SALES WORLDWIDE

+17.5%¹

ON AN
ORGANIC BASIS*

\$1.73²

ADJUSTED
DILUTED EPS

REFLECTS
31%³

IN ADJUSTED EPS
GROWTH VERSUS
PRIOR YEAR

CONTINUE TO FORECAST STRONG
FULL-YEAR 2022 EPS GROWTH

AT LEAST \$4.70⁴

In adjusted diluted EPS

BUSINESS HIGHLIGHTS

INNOVATION IN HEART TECH

- ▶ FDA approval for Aveir™ single-chamber leadless pacemaker that does not require leads to deliver therapy
- ▶ Expanded indication for CardioMEMS™ HF System, making this remote monitoring technology accessible to more people with earlier-stage heart failure



DIABETES CARE GLOBAL LEADERSHIP

- ▶ **26%⁵** SALES GROWTH WITH
~\$1B IN FREESTYLE
LIBRE^{®†} SALES
- ▶ FreeStyle Libre is the first and only CGM with expanded reimbursement in Japan to include all people with diabetes who use insulin



BUSINESS UNIT SALES



\$3.6B

MEDICAL DEVICES



\$5.3B

DIAGNOSTICS



\$1.1B

ESTABLISHED
PHARMACEUTICALS



\$1.9B

NUTRITION

STRENGTH IN DIAGNOSTICS

- ▶ **35%⁶** SALES GROWTH
IN **DIAGNOSTICS**
- ▶ \$3.3B in COVID-19 testing sales during the first quarter



*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 20, 2022, available at www.abbottinvestor.com. 1. On a GAAP basis, first-quarter Abbott sales increased 13.8%. 2. First-quarter GAAP diluted EPS was \$1.37. 3. On a GAAP basis, diluted EPS reflects growth of 37%. 4. Abbott projects full-year 2022 diluted earnings per share under GAAP of at least \$3.35. Abbott forecasts specified items for the full-year 2022 of \$1.35 per share primarily related to intangible amortization, costs related to a voluntary recall, expenses associated with acquisitions, restructurings and cost reduction initiatives, and other net expenses. Excluding specified items, projected adjusted diluted earnings per share of at least \$4.70 remains unchanged for the full-year 2022. 5. On a GAAP basis, first-quarter FreeStyle Libre sales increased 20%. 6. On a GAAP basis, first-quarter Diagnostics sales increased 32%. † Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.